TY - JOUR
T1 - Ribosomal antibiotics
T2 - Contemporary challenges
AU - Auerbach-Nevo, Tamar
AU - Baram, David
AU - Bashan, Anat
AU - Belousoff, Matthew
AU - Breiner, Elinor
AU - Davidovich, Chen
AU - Cimicata, Giuseppe
AU - Eyal, Zohar
AU - Halfon, Yehuda
AU - Krupkin, Miri
AU - Matzov, Donna
AU - Metz, Markus
AU - Rufayda, Mruwat
AU - Peretz, Moshe
AU - Pick, Ophir
AU - Pyetan, Erez
AU - Rozenberg, Haim
AU - Shalev-Benami, Moran
AU - Wekselman, Itai
AU - Zarivach, Raz
AU - Zimmerman, Ella
AU - Assis, Nofar
AU - Bloch, Joel
AU - Israeli, Hadar
AU - Kalaora, Rinat
AU - Lim, Lisha
AU - Sade-Falk, Ofir
AU - Shapira, Tal
AU - Taha-Salaime, Leena
AU - Tang, Hua
AU - Yonath, Ada
N1 - Publisher Copyright:
© 2016 by the authors; licensee MDPI, Basel, Switzerland.
PY - 2016/9
Y1 - 2016/9
N2 - Most ribosomal antibiotics obstruct distinct ribosomal functions. In selected cases, in addition to paralyzing vital ribosomal tasks, some ribosomal antibiotics are involved in cellular regulation. Owing to the global rapid increase in the appearance of multi-drug resistance in pathogenic bacterial strains, and to the extremely slow progress in developing new antibiotics worldwide, it seems that, in addition to the traditional attempts at improving current antibiotics and the intensive screening for additional natural compounds, this field should undergo substantial conceptual revision. Here, we highlight several contemporary issues, including challenging the common preference of broad-range antibiotics; the marginal attention to alterations in the microbiome population resulting from antibiotics usage, and the insufficient awareness of ecological and environmental aspects of antibiotics usage. We also highlight recent advances in the identification of species-specific structural motifs that may be exploited for the design and the creation of novel, environmental friendly, degradable, antibiotic types, with a better distinction between pathogens and useful bacterial species in the microbiome. Thus, these studies are leading towards the design of "pathogen-specific antibiotics," in contrast to the current preference of broad range antibiotics, partially because it requires significant efforts in speeding up the discovery of the unique species motifs as well as the clinical pathogen identification.
AB - Most ribosomal antibiotics obstruct distinct ribosomal functions. In selected cases, in addition to paralyzing vital ribosomal tasks, some ribosomal antibiotics are involved in cellular regulation. Owing to the global rapid increase in the appearance of multi-drug resistance in pathogenic bacterial strains, and to the extremely slow progress in developing new antibiotics worldwide, it seems that, in addition to the traditional attempts at improving current antibiotics and the intensive screening for additional natural compounds, this field should undergo substantial conceptual revision. Here, we highlight several contemporary issues, including challenging the common preference of broad-range antibiotics; the marginal attention to alterations in the microbiome population resulting from antibiotics usage, and the insufficient awareness of ecological and environmental aspects of antibiotics usage. We also highlight recent advances in the identification of species-specific structural motifs that may be exploited for the design and the creation of novel, environmental friendly, degradable, antibiotic types, with a better distinction between pathogens and useful bacterial species in the microbiome. Thus, these studies are leading towards the design of "pathogen-specific antibiotics," in contrast to the current preference of broad range antibiotics, partially because it requires significant efforts in speeding up the discovery of the unique species motifs as well as the clinical pathogen identification.
KW - Microbiome
KW - Multi-drug resistance
KW - Novel degradable antibiotics
KW - Species-specific antibiotics susceptibility
UR - http://www.scopus.com/inward/record.url?scp=85019824413&partnerID=8YFLogxK
U2 - 10.3390/antibiotics5030024
DO - 10.3390/antibiotics5030024
M3 - Review article
AN - SCOPUS:85019824413
SN - 2079-6382
VL - 5
JO - Antibiotics
JF - Antibiotics
IS - 3
M1 - 24
ER -